A simple example is Bisantrene synergises with Doxorubicin and no other anthracyclines.
Another simple example is Bisantrene synergises with Doxorubicin only in Breast, Lung, and Ovarian cancer and AML.
Bisantrene demonstrating CPACS in Breast cancer alone would still drive insane value from here, but it would not be maximised for the potential.
Speculative M&A Transaction Analysis, page-756
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $273.5M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.61 | $159.4K | 98.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5684 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |